Shares of biotech company CureVac N.V. (CVAC) were in the spotlight on Thursday after the company’s fourth-quarter revenue ...

Q4 2024 Earnings Call Transcript April 10, 2025 CureVac N.V. misses on earnings expectations. Reported EPS is $-0.16564 EPS, ...

CureVac (CVAC) has reported its fourth quarter 2024 financial results, generating mixed reactions from investors as the company balances ...

CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2024 and Provides Business Update 10.04.2025 / 13:12 CET/CEST The issuer is solely responsible for the content of this ...

CureVac NV (CVAC) reports a robust financial position with a significant licensing agreement with GSK, despite challenges in ...

Welcome to CureVac fourth-quarter and full year 2024 financial results and business update call. (Operator Instructions) As a reminder, this conference is being recorded. It is now my pleasure to ...

Analysts estimate that CureVac will report an earnings per share (EPS) of $-0.09. Investors in CureVac are eagerly awaiting ...

Curevac NV announced that the FDA has cleared its IND application for a phase I clinical study of CVHNLC in patients with ...

Shares of CureVac climbed after the European Patent Office confirmed the validity of a patent that has been the subject of a lawsuit filed by BioNTech. The stock rose 7% to $2.99 on Friday.

Commenting on the quarter Dr. Alexander Zehnder, Chief Executive Officer of CureVac said: "The fourth quarter of 2024 marked a strong finish to a year of significant transformation for CureVac.

Greetings. Welcome to CureVac Fourth Quarter and Full Year 2024 Financial Results and Business Update Call. At this time, all participants are in a listen-only mode. A question-and-answer session ...

Completed enrollment of Part B of Phase 1 glioblastoma study with investigational precision immunotherapy CVGBM; Part B first data readout anticipated in H2 2025 Filed IND and CTA submissions for ...